EFFECTS OF PRAVASTATIN AND URSODEOXYCHOLIC ACID ON CHOLESTEROL AND BILE-ACID METABOLISM IN PATIENTS WITH CHOLESTEROL GALLSTONES

被引：25

作者：

OKAMOTO, S ^{[1
]}

NAKANO, K ^{[1
]}

KOSAHARA, K ^{[1
]}

KISHINAKA, M ^{[1
]}

ODA, H ^{[1
]}

ICHIMIYA, H ^{[1
]}

CHIJIIWA, K ^{[1
]}

KUROKI, S ^{[1
]}

机构：

[1] KYUSHU UNIV,FAC MED,DEPT SURG 1,3-1-1 MAIDASHI,HIGASHI KU,FUKUOKA 812,JAPAN

来源：

JOURNAL OF GASTROENTEROLOGY | 1994年 / 29卷 / 01期

关键词：

CHOLESTEROL; 7-ALPHA-HYDROXYLASE; 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE; NUCLEATION TIME; HYPERCHOLESTEROLEMIA; CHOLELITHIASIS; URSODEOXYCHOLIC ACID; PRAVASTATIN;

D O I：

10.1007/BF01229073

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

To investigate the effects of pravastatin and ursodeoxycholic acid (UDCA) on cholesterol and bile acid metabolism in humans, 41 patients with cholesterol gallstone disease were allocated to four groups and treated with pravastatin (20 mg/day), UDCA (600 mg/day), both pravastatin and UDCA, or neither drug (control) for 1-2 weeks prior to elective cholecystectomy. Cholesterol 7alpha-hydroxylase activity and serum levels of total 7alpha-hydroxycholesterol were significantly increased by pravastatin and unaffected by UDCA. 3-Hydroxy-3-methylglutaryl coenzyme A reductase activity was markedly increased by pravastatin and decreased by UDCA. UDCA significantly decreased biliary cholesterol concentration and the cholesterol saturation index and prolonged the nucleation time; however, pravastatin alone had little effect on biliary lithogenicity. Serum total and low-density lipoprotein (LDL)-cholesterol levels were reduced most by the combined administration of pravastatin and UDCA. In conclusion, at a dose of 20 mg/day, pravastatin increased bile acid synthesis but did not decrease biliary lithogenicity. UDCA had no significant effect on bile acid synthesis, but markedly decreased biliary lithogenicity.

引用

页码：47 / 55

页数：9

共 46 条

[1]

Nakaya N., Homma Y., Tamachi H., Et al., The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects, JAMA, 257, pp. 3088-3093, (1987)

[2]

Therapeutic response to lovastation (mevinolin) in nonfamilial hypercholesterolemia: A multicenter study, JAMA, 256, pp. 2829-2834, (1986)

[3]

Hoeg J.M., Brewer H.B., 3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors in the treatment of hypercholesterolemia, JAMA, 258, pp. 3532-3536, (1987)

[4]

Grundy S.M., HMG-CoA reductase inhibitors for treatment of hypercholesterolemia, N Engl J Med, 319, pp. 24-33, (1988)

[5]

Hoogerbrugge V.D., Linden N., De Rooy F.W.M., Jansen H., Et al., Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia, Gut, 31, pp. 348-350, (1990)

[6]

Reihner E., Rudling M., Stahlberg D., Et al., Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol, N Engl J Med, 323, pp. 224-228, (1990)

[7]

Reihner E., Bjorkhem I., Angelin B., Et al., Bile acid synthesis in humans: Regulation of hepatic microsomal choiesterol 7αhydroxylase activity, Gastroenterology, 97, pp. 1498-1505, (1989)

[8]

Logan G.M., Duane W.C., Lovastatin added to ursodeoxycholic acid further reduces biliary cholesterol saturation, Gastroenterology, 98, pp. 1572-1576, (1990)

[9]

Yamashita H., Kuroki S., Nakayama F., Assay of cholesterol 7αhydroxylase utilizing a silica cartridge column and 5α-cholestane-3β,7β-diol as an internal standard, J Chromatogr, 496, pp. 255-268, (1989)

[10]

Reihner E., Angelin B., Rudling M., Et al., Regulation of hepatic cholesterol metabolism in humans: Stimulatory effects of cholestyramine on HMG-CoA reductase activity and low density lipoprotein receptor expression in gallstone patients, J Lipid Res, 31, pp. 2219-2226, (1990)

← 1 2 3 4 5 →